MyCural raises bridge round to advance cancer drug development
MyCural Therapeutics, that has been part of NOME since the start of the year, has secured a bridge round to accelerate the development of its drug candidates targeting high-risk cancers. Founded in 2022 by researchers from Karolinska Institutet, Linköping University, and Uppsala University, ...